Qlife Holding AB (QLIFE) AI Stock Analysis

• Market Cap: kr30.50M
• Dividend Yield: N/A
• Average Volume (3M): 97.19K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.58
• Revenue Growth: 376.81%
• EPS Growth: 97.95%
• Country: SE
• Employees: 3
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.73
• Shares Outstanding: 15,679,521
• 10 Day Avg. Volume: 81,486
• 30 Day Avg. Volume: 97,188
• PEG Ratio: -0.76
• Price to Book (P/B): -911.64
• Price to Sales (P/S): 26054.69
• P/FCF Ratio: -24.05
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: kr2.00 ▼(-33.55% Downside)

The score is primarily constrained by very weak financial performance (tiny revenue base, persistent losses, significant cash burn, and negative equity). Technicals are mixed but lean weak given the price below key longer-term moving averages, and valuation is unattractive/unclear due to negative earnings and no dividend support.

Positive Factors

Strong Revenue Growth Trend

The company reports very high year-over-year revenue growth percentage, indicating early product traction. For a diagnostic platform, sustained multi-quarter growth from a small base can signal improving market adoption and customer uptake, supporting longer-term scaling if execution continues.

Focused Diagnostic Platform

A clear strategic focus on personalized medicine and point-of-care diagnostics aligns with durable healthcare trends. Platform products plus consumables create potential recurring revenue streams and partnership opportunities with hospitals and pharma, which supports long-term commercial scalability if clinical validation and sales execution progress.

Cash vs. Accounting Loss Signal

Free cash flow loss being smaller than net loss suggests a portion of recorded losses are non-cash (e.g., accounting charges). This dynamic can extend runway versus headline net loss, providing management more time to execute commercialization or secure funding, which is important for a capital-intensive biotech ramp.

Negative Factors

Very Weak Financial Performance

Absolute revenue remains immaterial (TTM ~329k) while the company reports large losses at gross, operating and net levels. This mismatch between revenue scale and cost base reduces resilience to shocks and means several quarters of consistent execution and new sales are required before profitability or self-funded growth become realistic.

Negative Shareholders' Equity

A negative shareholders' equity position signals accumulated losses and constrains financial flexibility. With equity deficits, leverage is effectively high versus a small asset base, increasing refinancing and dilution risk and reducing the company's ability to absorb setbacks or fund growth without external capital injections.

Sustained Cash Burn

Persistent and sizable operating and free cash flow deficits highlight ongoing funding needs. Continuous cash burn elevates short-to-medium term solvency risk, forces reliance on external financing or dilutive capital raises, and limits the firm's ability to invest organically in commercial expansion or R&D without securing new liquidity.

Qlife Holding AB Business Overview & Revenue Model

Company Description

Qlife Holding AB (QLIFE) is a biotechnology company based in Sweden, specializing in the development of advanced diagnostic tools aimed at improving patient care and health outcomes. The company focuses on innovative solutions in the healthcare sector, particularly in the areas of personalized medicine and point-of-care diagnostics. Qlife's core products include its proprietary diagnostic platforms, which utilize advanced technology to deliver rapid and accurate health assessments.

How the Company Makes Money

QLIFE generates revenue primarily through the sale of its diagnostic products and services. The company offers its proprietary testing platforms to hospitals, clinics, and laboratories, which pay for the devices and associated consumables. Additionally, Qlife may engage in partnerships with healthcare organizations and pharmaceutical companies to develop customized diagnostic solutions, leading to revenue-sharing agreements. The company also explores opportunities in research collaborations and grants, which can provide additional funding and support for its product development initiatives. Continued growth may be driven by expanding its market presence and enhancing product offerings to meet the evolving needs of the healthcare industry.

Qlife Holding AB Financial Statement Overview

Summary

Overall financial quality is very weak: minimal TTM revenue (329k) with heavy losses at gross/operating/net levels, continued operating cash burn (TTM operating cash flow -15.6m; free cash flow -24.3m), and a stressed balance sheet with negative equity (TTM -5.3m), increasing financing and dilution/solvency risk.

Income Statement

Profitability is very weak. In TTM (Trailing-Twelve-Months), revenue is still minimal (329k) and the company is loss-making at every major level, with deeply negative gross, operating, and net margins. While TTM (Trailing-Twelve-Months) revenue growth is positive versus the prior annual period, the absolute revenue base remains too small to offset the cost structure, and the business has shown large and volatile losses across recent years.

Balance Sheet

The balance sheet shows elevated financial risk driven by negative shareholders’ equity in the most recent periods (TTM (Trailing-Twelve-Months) equity at -5.3m; 2024 at -1.4m), which limits financial flexibility. Total debt is moderate in absolute terms (about 8.5–8.7m recently), but leverage is effectively high given the equity deficit. Total assets are relatively small (TTM (Trailing-Twelve-Months) ~12.7m), and the capital structure has deteriorated materially from 2021–2022 when equity was positive.

Cash Flow

Cash generation is weak with continued cash burn. TTM (Trailing-Twelve-Months) operating cash flow is negative (-15.6m) and free cash flow is also deeply negative (-24.3m), with free cash flow declining versus the prior annual period. A partial positive is that free cash flow loss is smaller than net loss in recent periods (free cash flow to net income above 1), but the core issue remains sustained negative operating cash flow and ongoing funding needs.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	329.00K	50.00K	244.00K	17.99M	39.61M	20.75M
Gross Profit	-7.11M	-158.00K	-6.31M	-10.75M	44.54M	35.68M
EBITDA	-24.29M	-12.46M	-150.50M	-78.05M	-35.13M	-19.49M
Net Income	-25.16M	-55.98M	-159.96M	-93.14M	-38.80M	-20.20M
Balance Sheet
Total Assets	12.70M	11.64M	39.05M	192.65M	193.44M	127.19M
Cash, Cash Equivalents and Short-Term Investments	2.81M	2.71M	1.66M	14.55M	73.46M	20.82M
Total Debt	8.55M	8.70M	20.25M	52.44M	4.72M	3.96M
Total Liabilities	17.96M	13.07M	62.17M	101.50M	30.26M	37.64M
Stockholders Equity	-5.27M	-1.43M	-23.12M	91.15M	132.50M	89.55M
Cash Flow
Free Cash Flow	-24.30M	-54.17M	-62.64M	-90.67M	-52.82M	-43.66M
Operating Cash Flow	-15.60M	-37.37M	-41.80M	-47.73M	-26.05M	-16.83M
Investing Cash Flow	-8.70M	-16.80M	-20.84M	-42.94M	-26.77M	-26.83M
Financing Cash Flow	23.98M	55.23M	49.00M	32.73M	106.02M	58.91M

Qlife Holding AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.01
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:QLIFE, the sentiment is Negative. The current price of 3.01 is above the 20-day moving average (MA) of 2.22, above the 50-day MA of 2.07, and above the 200-day MA of 2.73, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 42.67 is Neutral, neither overbought nor oversold. The STOCH value of 12.85 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:QLIFE.

Qlife Holding AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SDOS	50 Neutral	kr59.58M	-43.18	―	―	―	―
LXB	44 Neutral	kr64.68M	-3.02	-60.20%	―	163.12%	30.50%
HEART	43 Neutral	kr140.96M	-0.85	―	―	―	―
QLIFE	42 Neutral	kr30.50M	-0.38	―	―	376.81%	97.95%
SPEC	42 Neutral	kr71.50M	-0.48	-50.21%	―	―	-108.64%
CMH	41 Neutral	kr2.27M	-0.06	―	―	―	―